FDA Peptide Reclassification 2026: RFK Jr., Category 2, and What It Means for Researchers
RFK Jr. has signaled potential changes to the FDA's Category 2 peptide list — which currently bans BPC-157, TB-500, and 17 other compounds from compounding pharmacies. Here's the current regulatory landscape and what may change.
The FDA's 2023 decision to place BPC-157, TB-500, and 17 other peptides on its Category 2 "substances with safety concerns" list sent shockwaves through the research peptide community. Now, in early 2026, regulatory discussions are intensifying — and HHS Secretary Robert F. Kennedy Jr. has publicly signaled interest in revisiting these restrictions.
What the Category 2 List Actually Means
The FDA's Category 2 classification under Section 503A of the Federal Food, Drug, and Cosmetic Act prohibits traditional compounding pharmacies from producing listed substances for human use. It does NOT:
- Make possession illegal for research purposes
- Prohibit sale as research chemicals
- Apply to laboratory or in vitro research settings
Research peptides like BPC-157 and TB-500 remain legal to purchase and use for legitimate laboratory research — they simply cannot be compounded by pharmacies for clinical use in humans.
The 19 Restricted Peptides
The current Category 2 list includes: BPC-157, TB-500 (Thymosin Beta-4), CJC-1295, Ipamorelin, GHRP-2, GHRP-6, Hexarelin, AOD-9604, Selank, Semax, Epithalon, GHK-Cu (injectable), PT-141, Thymosin Alpha-1, LL-37, KPV, Sermorelin (in some formulations), Tesamorelin (for non-approved uses), and Melanotan II.
RFK Jr.'s Signal and Industry Response
Recent public statements from HHS Secretary Kennedy, including comments during a Joe Rogan Experience appearance, have raised hopes among clinicians and researchers that some peptides could be moved off the restricted list. Kennedy's broader DOGE-adjacent regulatory skepticism has led many in the field to believe a policy review is plausible.
Industry groups including the Outsourcing Facilities Association (OFA) have filed legal challenges to the FDA's compounding authority. Courts have issued mixed rulings, with some temporary restraining orders allowing continued compounding while cases were litigated.
The FDA's Official Rationale
The agency's stated concern with research peptides centers on three risks:
1. Immunogenicity — peptides may trigger immune responses
2. Impurity profiles — manufacturing variability could introduce contaminants
3. Limited human safety data — most research is confined to animal models
Critics argue these concerns apply equally to hundreds of approved drugs that had the same profile at an earlier stage of development — and that the restrictions disproportionately benefit pharmaceutical companies who hold patents on approved peptide drugs.
What Researchers Should Know
Regardless of regulatory developments at the compounding level, the research chemical classification remains stable. Researchers purchasing peptides with appropriate "not for human consumption" labeling for laboratory use operate in a well-established legal framework that is separate from the compounding pharmacy regulations.
The research peptide market exists precisely because laboratory investigation of these compounds is both legal and scientifically necessary. Peer-reviewed publications on BPC-157, TB-500, and other Category 2 peptides continue to appear in journals including PMC, Frontiers in Pharmacology, and Nature Medicine.
*All Aeterion Labs products are sold strictly for laboratory research purposes only. Not for human consumption.*